<i id='759D2C8102'><strike id='759D2C8102'><tt id='759D2C8102'><pre id='759D2C8102'></pre></tt></strike></i>
NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?
Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.
advertisement
Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We
read more
2:13TheZaporizhzhiaNuclearPowerPlantisshownoutsideEnerhodarintheZaporizhzhiaregion,Russian-controlle
read more
MikeReddyforSTATHealthcarecompaniesareracingtoincorporategenerativeAItoolsintotheirproductpipelinesa
read moreResidentsoftheJeninrefugeecampfledtheirhomesastheIsraelimilitarypressedaheadwithanoperationinthearea
